Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biocept Inc    BIOC

BIOCEPT INC (BIOC)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/17 09:14:21 pm
0.6764 USD   -17.24%
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2018 12/12/2018 12/13/2018 12/14/2018 12/17/2018 Date
0.838(c) 0.8417(c) 0.77(c) 0.8173(c) 0.6764 Last
319 825 157 675 219 144 353 811 262 945 Volume
-11.79% +0.44% -8.52% +6.14% -17.24% Change
More quotes
Financials (USD)
Sales 2018 3,39 M
EBIT 2018 -23,6 M
Net income 2018 -23,9 M
Debt 2018 -
Yield 2018 -
Sales 2019 5,00 M
EBIT 2019 -18,5 M
Net income 2019 -19,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,98x
Capi. / Sales2019 0,66x
Capitalization 3,32 M
More Financials
Company
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector... 
More about the company
Latest news on BIOCEPT INC
11/14BIOCEPT : Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/13BIOCEPT INC : Results of Operations and Financial Condition, Financial Statement..
AQ
11/07BIOCEPT : Announces New Executive Hires to its Sales and Marketing Organization
AQ
09/24BIOCEPT INC : Entry into a Material Definitive Agreement, Unregistered Sale of E..
AQ
08/14BIOCEPT INC : Results of Operations and Financial Condition, Financial Statement..
AQ
08/14BIOCEPT : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/13BIOCEPT INC : Material Modification to Rights of Security Holders, Amendments to..
AQ
07/25BIOCEPT INC : Other Events (form 8-K)
AQ
More news
Sector news : Diagnostic & Testing Substances
12/05PATRICK THOMAS : Medtronic Units Pay $31 Million in Justice Department Probe
DJ
11/30MEDTRONIC : Indiana Jury Returns Verdict of About $112 Million Against Company i..
DJ
11/21MEDTRONIC : to Buy Nutrition Data Company Nutrino Health
DJ
11/21DEXCOM : Revises Collaboration and License Pact With Alphabet's Verily
DJ
11/20GLOBAL MARKETS LIVE : Boston Scientific, SocGen, Nissan, Apple…
More sector news : Diagnostic & Testing Substances
Chart BIOCEPT INC
Duration : Period :
Biocept Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCEPT INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 5,13 $
Spread / Average Target 527%
EPS Revisions
Managers
NameTitle
Michael W. Nall President, Chief Executive Officer & Director
David F. Hale Non-Executive Chairman
Timothy C. Kennedy CFO, Senior VP-Operations & Secretary
Lyle J. Arnold Chief Scientific Officer & SVP-Research
Veena M. Singh Senior Vice President & Senior Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCEPT INC-96.07%3
BIOMÉRIEUX-19.67%8 030
DIASORIN-3.04%4 539
AUTOBIO DIAGNOSTICS CO LTD-0.60%3 218
SIEGFRIED HOLDING AG8.64%1 501
MACCURA BIOTECHNOLOGY CO LTD--.--%1 238